Global Neurology Academy

Rethinking Progression in Multiple Sclerosis
Rethinking Progression in Multiple Sclerosis
NeuroFrontiers
Rethinking Progression in Multiple Sclerosis
- Charles Turck, PharmD, BCPS, BCCCP
- Christopher Lock, MD
Who’s Missing from Multiple Sclerosis Research?
Who’s Missing from Multiple Sclerosis Research?
NeuroFrontiers
Who’s Missing from Multiple Sclerosis Research?
- Ashley Baker, MSN, PMHNP
- Ruth Ann Marrie, MD, PhD
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiers
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
NeuroFrontiers
GFAP and VEGF Trajectories in Adult Type 3 Spinal Muscular Atrophy Under Nusinersen
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
NeuroFrontiers
Advancing MS Care with Multimodal Aging Signatures and Proteomic Biomarkers
- Adil Harroud, MD
- Dylan Hamitouche
- Ryan Quigley
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
Global Neurology Academy
OCEANIC-STROKE Results: Asundexian for Secondary Stroke Prevention After Acute Non-Cardioembolic Stroke or High-Risk TIA
- Mike Sharma, MD, MSc, FRCPC
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
Global Neurology Academy
Beyond the Primary Endpoint: What OCEANIC-STROKE Subtype Analyses Reveal About Asundexian’s Potential
- Ashkan Shoamanesh, MD
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
On the Frontlines of Schizophrenia
Delivering a Hopeful, Recovery-Oriented Schizophrenia Diagnosis
- Alexandria May, PharmD, BCPS
- Apurva Bhatt, MD

Medical News

Medical News
Habitual Activity and Executive Function in Adolescents: Longitudinal Wearable Study
03/11/2026
Read more
Medical News
Sex Differences in Mouse Brain GLP‑1 Mapping: Clinical Implications
03/11/2026
Read more
Medical News
GLP-1 RAs and Substance Use Disorders: Findings from a Veteran Cohort
03/10/2026
Read more
Medical News
EEG Time‑Frequency Images Predict SSRI and rTMS Response
03/10/2026
Read more

See more news

CME/CE

CME/CE In-Person & Virtual Event
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
March 23, 2026
March 23, 2026
Boston, Massachusetts
1.00 credit Learn more
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
CME/CE In-Person Event
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
March 23, 2026
Boston, Massachusetts
1.00 credit Learn more
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
CME/CE Virtual Event
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
March 23, 2026
12:30 PM - 01:30 PM EDT
1.00 credit Learn more
Primary Care for the Brain: Prevention and Early Detection of Cognitive Decline
Primary Care for the Brain: Prevention and Early Detection of Cognitive Decline
CME/CE
Primary Care for the Brain: Prevention and Early Detection of Cognitive Decline
1.00 credit
- Emily D. Clark, DO
- Tracey M. Piparo, PA-C, CAQ-PMHC, DFAAPA
- Susan Scanland, MSN, CRNP, GNP-BC, CDP
- Anthony J. Viera, MD, MPH
1.00 credit

Clinical Practice

Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiers
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Strategies to Safeguard Brain Health in MS
Strategies to Safeguard Brain Health in MS
NeuroFrontiers
Strategies to Safeguard Brain Health in MS
- Christopher Lock, MD
Switching to Risdiplam Maintains Motor Gains in SMA Patients
Switching to Risdiplam Maintains Motor Gains in SMA Patients
AudioAbstracts
Switching to Risdiplam Maintains Motor Gains in SMA Patients
- Ryan Quigley
Multiple Sclerosis Without Borders: Taking a Global View
Multiple Sclerosis Without Borders: Taking a Global View
NeuroFrontiers
Multiple Sclerosis Without Borders: Taking a Global View
- Andrew Wilner, MD, FACP, FAAN
- Victor Rivera, MD

Programs

Understanding Accelerated Biological Aging in Pediatric MS
Understanding Accelerated Biological Aging in Pediatric MS
NeuroFrontiers
Understanding Accelerated Biological Aging in Pediatric MS
- Jennifer Yang, MD
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
NeuroFrontiers
Multiplex Proteomic Biomarkers in MS: Emerging Tools for Precision Care
- Raphael Schneider, MD, PhD, FRCPC, CIP
Evaluating Structured Interventions for Cognitive Support in MS
Evaluating Structured Interventions for Cognitive Support in MS
AudioAbstracts
Evaluating Structured Interventions for Cognitive Support in MS
- Hallie Blevins, PhD
Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS
NeuroFrontiers
Vitamin D3's Effects on Inflammatory and Oxidative Biomarkers in MS